Ask Thryv Live: Episode 1
Daphne Doucet Daphne Doucet

Ask Thryv Live: Episode 1

Thryv Therapeutics will be hosting our very first “Ask Thryv Live” on Tuesday, May 7th from 12:00 p.m. to 1:00 p.m. ET.

Read More
Shake it for Shea - Shea’s LQTS Story
Shared Stories Daphne Doucet Shared Stories Daphne Doucet

Shake it for Shea - Shea’s LQTS Story

Baby Shea came into the world, early, in dramatic style. She needed resuscitation immediately after birth, and on her second day of life, Shea’s heart went into a type of arrhythmia called Torsades de Pointes. Doctors estimated that Shea’s QT interval was over 700 (normal is <440ms).

Read More
Heather’s LQTS Story
Shared Stories Daphne Doucet Shared Stories Daphne Doucet

Heather’s LQTS Story

In February 2018, Heather, the Curriculum Director of her local school district, was joking and chatting with colleagues in the conference room. All of a sudden, she felt the room begin to spin, felt nauseous, and attempted to leave for the restroom. She managed only two steps towards the door before her heart stopped, and she dropped lifeless to the floor.

Read More
Azariah’s LQTS Story
Shared Stories Daphne Doucet Shared Stories Daphne Doucet

Azariah’s LQTS Story

Baby Azariah, whose name means ‘God is my help’, was born prematurely and spent 33 days in NICU (Neonatal intensive care unit). He was initially rushed to NICU due to an abnormal heart rate. Fortunately, the hospital had the state’s best paediatric electrophysiologist and diagnosed Azariah with a severely prolonged QT interval. He immediately started beta blockers, one current therapy for Long QT syndrome. Angela attributes this vital early intervention at only two days old to saving Azariah’s life.

Read More
SADS Live interview with Thryv Therapeutics
Inside Thryv Thryv Therapeutics Inside Thryv Thryv Therapeutics

SADS Live interview with Thryv Therapeutics

Three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program. We invite you to watch this interview to learn more about our passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments.

Read More